Clinical trials: Glomerulopathy
Treatment
Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy
The purpose of this study is to assess the efficacy and safety of immunoadsorption in the treatment of lipoprotein glomerulopathy.
- Trial name
- NCT00302510
- Testing
- immunoadsorption
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Sickle Cell Disease, Renal Disease
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
- Conditions
- Sickle Cell Disease, Renal Disease, Glomerular Disease
- Trial name
- NCT04380610
- Testing
- iohexol GFR
- Where
- 4 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Chronic Kidney Disease, Glomerulopathy
Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center
Chronic kidney disease (CKD) affects approximately 26 million Americans and disproportionately manifests in specific race and ethnic groups. Patients burdened with CKD have significant morbidity and reduced life expectancy.
- Trial name
- C-PROBE (NCT01016613)
- Where
- 5 sites in United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Glomerular Disease, Bone Diseases, Metabolic
The Impact of Glomerular Disorders on Bone Quality and Strength
The primary objectives of this study are to: (1) determine the impact of glomerular disease on bone strength and (2) investigate the pathophysiologic underpinnings of impaired bone strength in glomerular disease.
- Conditions
- Glomerular Disease, Bone Diseases, Metabolic, Bone Fracture
- Trial name
- BoneGN (NCT04528446)
- Testing
- Dual-energy X-ray absorptiometry, High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT), Blood draw and Urine collection
- Where
- 2 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Columbia University
Glomerulopathy, C3G
Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGN
This is a prospective, multicenter, non-interventional, observational pharmacological real-world study to characterize longitudinal changes in ex vivo biomarkers of complement activation in patients with C3G and primary IC-MPGN…
- Conditions
- Glomerulopathy, C3G, Membranoproliferative Glomerulonephritis (MPGN)
- Trial name
- COMPASS (NCT07904338)
- Testing
- Blood sample
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research